Positive data from first part of Cytokinetics' PhII ALS trial
This article was originally published in Scrip
Executive Summary
Cytokinetics has reported positive results from the first cohort (Part A) of an ongoing Phase II trial of CK-2017357, its lead drug candidate from its skeletal muscle contractility programme, showing that the product was well tolerated in patients with amyotrophic lateral sclerosis (ALS).